TRIAL DETAIL
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery
|
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 07/01/2008 |
Age of Trial (yrs) 15.8 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor+ VEGF inhibitor (antibody) |
|||
Strategy: |
Block KIT + Block blood vessel growth |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
090019, 09-C-0019 |
|||
Sponsor: |
NCI |
|||
Patient Contact: |
Nicole D. Houston, R.N. (301) 443-6431 houstonnd@mail.nih.gov
Elise C Kohn, M.D. (301) 402-1357 kohne@mail.nih.gov |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
Randomized |
|||
IV or Oral: |
Oral
Intravenous |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
9000 Rockville Pike
|
Bethesda |
MD |
20892 |
USA |